Intellectual
Property


Recce Pharmaceuticals currently has four wholly owned patent families, which include over 40 patents or patent applications and are constantly expanding, broadening, and developing the intellectual property portfolio.
Recce is committed to protecting its intellectual property estate of patent rights and trade secrets as well as the potential commercial and/or clinical advantages this protection provides for its proprietary technology.
Recce’s patent portfolio includes issued patents and patent applications in the world’s major markets, including the United States, Europe, Japan, China and Australia.
Patent Families
Protecting Recce’s unique and highly economical manufacturing process.
Filed | Expiry | Status |
---|---|---|
![]() ![]() ![]() ![]() Australia |
2028 | Granted |
![]() ![]() ![]() ![]() USA |
2029 | Granted |
![]() ![]() ![]() ![]() Europe |
2028 | Granted |
![]() ![]() ![]() ![]() Germany |
2028 | Granted |
![]() ![]() ![]() ![]() Spain |
2028 | Granted |
![]() ![]() ![]() ![]() France |
2029 | Granted |
![]() ![]() ![]() ![]() UK |
2028 | Granted |
![]() ![]() ![]() ![]() Italy |
2028 | Granted |
![]() ![]() ![]() ![]() Sweden |
2028 | Granted |
![]() ![]() ![]() ![]() Japan |
2028 | Granted |
![]() ![]() ![]() ![]() China |
2028 | Granted |
Protecting Recce’s drug delivery opportunities.
Filed | Expiry | Status |
---|---|---|
![]() ![]() ![]() ![]() Australia |
2035 | Granted |
![]() ![]() ![]() ![]() USA |
2035 | Granted |
![]() ![]() ![]() ![]() Europe |
2035 | Granted |
![]() ![]() ![]() ![]() Germany |
2035 | Granted |
![]() ![]() ![]() ![]() Spain |
2035 | Granted |
![]() ![]() ![]() ![]() France |
2035 | Granted |
![]() ![]() ![]() ![]() UK |
2035 | Granted |
![]() ![]() ![]() ![]() Italy |
2035 | Granted |
![]() ![]() ![]() ![]() Sweden |
2035 | Granted |
![]() ![]() ![]() ![]() Japan |
2035 | Granted |
![]() ![]() ![]() ![]() China |
2035 | Granted |
Anti-virus agent and method for treatment of viral infection.
Filed | Expiry | Status |
---|---|---|
![]() ![]() ![]() ![]() Australia |
2037 | Granted |
![]() ![]() ![]() ![]() USA |
2037 | Granted |
![]() ![]() ![]() ![]() Europe |
2037 | Granted |
![]() ![]() ![]() ![]() Germany |
2037 | Granted |
![]() ![]() ![]() ![]() Spain |
2037 | Granted |
![]() ![]() ![]() ![]() France |
2037 | Granted |
![]() ![]() ![]() ![]() UK |
2037 | Granted |
![]() ![]() ![]() ![]() Italy |
2037 | Granted |
![]() ![]() ![]() ![]() Sweden |
2037 | Granted |
![]() ![]() ![]() ![]() Japan |
2037 | Granted |
![]() ![]() ![]() ![]() China |
2037 | Granted |
![]() ![]() Hong Kong |
2037 | Granted |
Process for Preparation of Biologically Active Copolymer.
Filed | Expiry | Status |
---|---|---|
![]() ![]() Australia | 2041 | Granted |
![]() ![]() Israel | 2041 | Granted |
![]() ![]() Canada | 2041 | Granted |
Protecting RECCE® for use on antibiotic and pharmaceutical products and services
Filed | Expiry | Status |
---|---|---|
![]() ![]() Australia |
2026 | Registered |
![]() ![]() USA |
2026 | Registered |
![]() ![]() Europe |
2026 | Registered |
![]() ![]() Japan |
2026 | Registered |
![]() ![]() China |
2026 | Registered |
![]() ![]() Hong Kong |
2032 | Registered |
![]() ![]() Vietnam |
2033 | Registered |
![]() ![]() Canada |
2034 | Registered |